Skip to main content

Table 2 Mean difference of coagulation factors among different lipid-lowering drugs users

From: Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

  Mean level Mean difference (95% CI) Adjusted mean difference a (95% CI)
Fibrinogen, mg/dL
 Fibrate/Niacin users (n = 21) 294.4 ± 52.5 Reference Reference
 All statin users (n = 1007) 316.1 ± 68.4 21.6 (−7.8 to 51.1) 19.1 (−10.0 to 48.2)
 Rosuvastatin users (n = 104) 316.3 ± 54.0 21.8 (−3.6 to 47.3) 20.7 (−6.2 to 47.6)
 Other statin users (n = 903) 316.0 ± 69.9 21.6 (−8.5 to 51.7) 18.6 (− 11.0 to 48.4)
FVIII, IU/dL
 Fibrate/Niacin users (n = 21) 142.1 ± 34.4 Reference Reference
 All statin users (n = 1008) 130.5 ± 36.5 −11.5 (− 27.3 to 4.2) − 15.8 (−31.6 to 0.003)
 Rosuvastatin users (n = 104) 127.2 ± 33.1 −14.8 (− 30.6 to 0.9) − 17.6 (− 33.8 to − 1.3)
 Other statin users (n = 904) 130.9 ± 36.6 −11.5 (− 27.1 to 4.7) −15.5 (− 31.5 to 0.5)
FIX, IU/dL
 Fibrate/Niacin users (n = 21) 136.5 ± 29.2 Reference Reference
 All statin users (n = 1008) 125.2 ± 27.6 −11.2 (−23.2 to 0.7) − 11.3 (− 23.2 to 0.4)
 Rosuvastatin users (n = 104) 122.4 ± 30.5 − 14.1 (− 28.4 to 0.2) − 14.9 (− 29.7 to − 0.08)
 Other statin users (n = 904) 125.6 ± 27.3 −10.9 (− 22.7 to 0.9) − 11.0 (− 22.7 to 0.7)
FXI, IU/dL
 Fibrate/Niacin users (n = 21) 137.6 ± 28.0 Reference Reference
 All statin users (n = 1008) 120.4 ± 20.9 −17.1 (− 30.0 to − 4.3) −18.3 (− 27.3 to − 9.4)
 Rosuvastatin users (n = 104) 120.4 ± 18.4 − 17.2 (− 26.8 to −7.5) − 17.6 (− 27.4 to − 7.7)
 Other statin users (n = 904) 120.4 ± 21.2 −17.1 (− 26.4 to − 7.9) − 18.3 (− 27.4 to − 9.2)
  1. CI confidence interval
  2. aadjusted for age, sex, body mass index, hypertension, smoking, diabetes, cardiovascular diseases